ClinicalTrials.gg
Active, not recruitingNCT02251665Updated Nov 9, 2023

National Cerebral and Cardiovascular Center (NCVC) Stroke Registry

An observational study in Stroke, Acute, sponsored by National Cerebral and Cardiovascular Center, Japan. Active, not recruiting at 1 site in Japan. Per ClinicalTrials.gov, last updated 2023-11-09.

Sponsored by National Cerebral and Cardiovascular Center, Japan · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
5,374
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Stroke with a site in Japan — 7 open to participants now, 12 under way, 3 of them phase 3. Stroke · Japan.

Enrollment
6th of 15
5,374 · median 3,026
Started
2016
with 4 others
Observational
15 of 69
2 open now
Primary completion
2027-03
later than 2 of 11 live
Registered
41st of 69
by date
Lead sponsor
4 of 69
National Cerebral and Cardiovascular Center, Japan

Among the 69 studies in Stroke with a site in Japan, this one is the 6th largest by enrollment of the 15 observational ones that give a count, is one of 5 that started in 2016, is one of 15 observational ones, reaches primary completion later than 2 of the 11 other live ones, and was the 41st registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

7 of the 69 studies in Stroke with a site in Japan are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Stroke with a site in Japan, or all of them as a file.
02

Study summary

A single-center registry of patients with acute ischemic stroke, intracerebral hemorrhage, and transient ischemic attack (TIA) who are emergently managed in the stroke care unit in the National Cerebral and Cardiovascular Center (NCVC) to determine change in underlying characteristics, stroke features and severity, process for diagnosis and acute treatment, and long-term outcomes of stroke/TIA patients over the years.

Read the detailed description

This is a single-center registry of consecutive patients with acute ischemic stroke, intracerebral hemorrhage, and transient ischemic attack (TIA) who are emergently managed in the stroke care unit in the National Cerebral and Cardiovascular Center, a flagship stroke center in Japan.

Neurological emergencies other than stroke/TIA and subclinical cerebrobvascular inpatients are also enrolled.

Data are collected and analyzed to determine change in underlying characteristics, stroke features and severity, process for diagnosis and acute treatment, and long-term outcomes of stroke/TIA patients over the years.

The National Cerebral and Cardiovascular Center was founded in 1977 in Suita, Osaka, in order to provide the public with the most advanced treatment for cardiovascular and cerebrovascular diseases and to conduct the highest level of basic as well as applied research on the cardiovascular and cerebrovascular systems.

03

Conditions studied

  • Stroke, Acute

Keywords

  • Acute ischemic stroke
  • Acute intracerebral hemorrhage
  • Transient ischemic attack
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Inpatients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A patient with acute ischemic stroke, intracerebral hemorrhage, and who are emergently managed in the stroke care unit or stroke units in the National Cerebral and Cardiovascular Center (NCVC)
  2. Consent to participate in the registration by a patient or relatives obtained using an opt-out approach by the demonstrating contents of the registration on the hospital bulletin board

Exclusion criteria

Exclusion Criteria:

  1. Patients considered by the investigator to be unsuitable for participating in this registry
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
5,374 participants (actual)
Patient registry
No

Groups and cohorts

  • Acute ischemic stroke, acute ICH, TIA

    Consecutive patients with acute ischemic stroke, intracerebral hemorrhage, and transient ischemic attack who are emergently managed in the stroke care unit or stroke units in the National Cerebral and Cardiovascular Center

    Other: No intervention

Interventions

  • OtherNo intervention

    a single-center prospective observational study

06

What researchers measure

Primary outcomes

  1. The modified Rankin Scale (mRS), a measure of disability

    mRS scores range from 0 (no symptoms at all) to 6 (death)

    Time frame: 3 monhts

Secondary outcomes

  1. Number of participants

    Also assessing underlying patients' characteristics prior to index stroke/TIA

    Time frame: at entry

  2. National Institutes of Health Stroke Scale score

    Also assessing neurological and cognitive states

    Time frame: at entry

  3. Volume of culprit infarcts/hematoma

    ASPECTS on DWI for ischemia or hematoma volume using the ABC/2 method

    Time frame: at entry

  4. The modified Rankin Scale (mRS), a measure of disability

    mRS scores range from 0 (no symptoms at all) to 6 (death). Participants will be followed at hospital discharge, an expected average of 3 weeks.

    Time frame: around 3 weeks

  5. The modified Rankin Scale (mRS), a measure of disability

    mRS scores range from 0 (no symptoms at all) to 6 (death)

    Time frame: 1 year

  6. Events of cardiovascular diseases including stroke/TIA

    Participants will be followed at hospital discharge, an expected average of 3 weeks.

    Time frame: around 3 weeks

  7. Events of cardiovascular diseases including stroke/TIA

    Time frame: 3 months

  8. Events of cardiovascular diseases including stroke/TIA

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Publications

  • Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol. 2014 Aug;13(8):823-33. doi: 10.1016/S1474-4422(14)70026-2. PubMed 25030514 ↗
  • Osaki M, Miyashita F, Koga M, Fukuda M, Shigehatake Y, Nagatsuka K, Minematsu K, Toyoda K. Simple clinical predictors of stroke outcome based on National Institutes of Health Stroke scale score during 1-h recombinant tissue-type plasminogen activator infusion. Eur J Neurol. 2014 Mar;21(3):411-8. doi: 10.1111/ene.12294. Epub 2013 Nov 7. PubMed 24200315 ↗
  • Sakamoto Y, Sato S, Kuronuma Y, Nagatsuka K, Minematsu K, Toyoda K. Factors associated with proximal carotid axis occlusion in patients with acute stroke and atrial fibrillation. J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):799-804. doi: 10.1016/j.jstrokecerebrovasdis.2013.07.002. Epub 2013 Oct 6. PubMed 24103668 ↗
  • Sato S, Uehara T, Hayakawa M, Nagatsuka K, Minematsu K, Toyoda K. Intra- and extracranial atherosclerotic disease in acute spontaneous intracerebral hemorrhage. J Neurol Sci. 2013 Sep 15;332(1-2):116-20. doi: 10.1016/j.jns.2013.06.031. Epub 2013 Jul 13. PubMed 23859180 ↗
  • Kobayashi J, Uehara T, Toyoda K, Endo K, Ohara T, Fujinami J, Nagatsuka K, Minematsu K. Clinical significance of fluid-attenuated inversion recovery vascular hyperintensities in transient ischemic attack. Stroke. 2013 Jun;44(6):1635-40. doi: 10.1161/STROKEAHA.111.000787. Epub 2013 May 7. PubMed 23652273 ↗
  • Tanaka K, Koga M, Sato K, Suzuki R, Minematsu K, Toyoda K. Three-dimensional analysis of the left atrial appendage for detecting paroxysmal atrial fibrillation in acute ischemic stroke. Int J Stroke. 2014 Dec;9(8):1045-51. doi: 10.1111/ijs.12268. Epub 2014 Mar 13. PubMed 24621380 ↗
  • Tomii Y, Toyoda K, Suzuki R, Naganuma M, Fujinami J, Yokota C, Minematsu K. Effects of 24-hour blood pressure and heart rate recorded with ambulatory blood pressure monitoring on recovery from acute ischemic stroke. Stroke. 2011 Dec;42(12):3511-7. doi: 10.1161/STROKEAHA.111.628586. Epub 2011 Sep 29. PubMed 21960578 ↗
  • Koga M, Arihiro S, Miyashita F, Yamamoto H, Yamada N, Nagatsuka K, Minematsu K, Toyoda K. Factors associated with early recanalization failure following intravenous rt-PA therapy for ischemic stroke. Cerebrovasc Dis. 2013;36(4):299-305. doi: 10.1159/000355054. Epub 2013 Oct 16. PubMed 24135558 ↗
  • Inoue Y, Miyashita F, Koga M, Minematsu K, Toyoda K. Unclear-onset intracerebral hemorrhage: Clinical characteristics, hematoma features, and outcomes. Int J Stroke. 2017 Dec;12(9):961-968. doi: 10.1177/1747493017702664. Epub 2017 Mar 31. PubMed 28361615 ↗
  • Okada T, Yoshimoto T, Wada S, Yoshimura S, Chiba T, Egashira S, Kimura S, Shiozawa M, Inoue M, Ihara M, Toyoda K, Takashima H, Koga M. Intravenous Thrombolysis With Alteplase at 0.6 mg/kg in Patients With Ischemic Stroke Taking Direct Oral Anticoagulants. J Am Heart Assoc. 2022 Oct 4;11(19):e025809. doi: 10.1161/JAHA.122.025809. Epub 2022 Sep 21. PubMed 36129032 ↗
  • Koge J, Tanaka K, Yoshimoto T, Shiozawa M, Kushi Y, Ohta T, Satow T, Kataoka H, Ihara M, Koga M, Isobe N, Toyoda K. Internal Carotid Artery Tortuosity: Impact on Mechanical Thrombectomy. Stroke. 2022 Aug;53(8):2458-2467. doi: 10.1161/STROKEAHA.121.037904. Epub 2022 Apr 11. PubMed 35400203 ↗
  • Inoue M, Yoshimoto T, Tanaka K, Koge J, Shiozawa M, Nishii T, Ohta Y, Fukuda T, Satow T, Kataoka H, Yamagami H, Ihara M, Koga M, Mlynash M, Albers GW, Toyoda K. Mechanical Thrombectomy Up to 24 Hours in Large Vessel Occlusions and Infarct Velocity Assessment. J Am Heart Assoc. 2021 Dec 21;10(24):e022880. doi: 10.1161/JAHA.121.022880. Epub 2021 Dec 10. PubMed 34889115 ↗
  • Yoshimoto T, Shiozawa M, Koge J, Inoue M, Koga M, Ihara M, Toyoda K. Evaluation of Workflow Delays in Stroke Reperfusion Therapy: A Comparison between the Year-Long Pre-COVID-19 Period and the with-COVID-19 Period. J Atheroscler Thromb. 2022 Jul 1;29(7):1095-1107. doi: 10.5551/jat.63090. Epub 2021 Aug 13. PubMed 34393139 ↗
  • Koge J, Tanaka K, Yoshimoto T, Shiozawa M, Yamagami H, Satow T, Takahashi JC, Ihara M, Koga M, Kira JI, Toyoda K. Early recurrent ischemic events after mechanical thrombectomy: effect of post-treatment intracranial hemorrhage. J Neurol. 2021 Aug;268(8):2810-2820. doi: 10.1007/s00415-021-10449-1. Epub 2021 Feb 16. PubMed 33594451 ↗
  • Yoshimoto T, Inoue M, Yamagami H, Fujita K, Tanaka K, Ando D, Sonoda K, Kamogawa N, Koga M, Ihara M, Toyoda K. Use of Diffusion-Weighted Imaging-Alberta Stroke Program Early Computed Tomography Score (DWI-ASPECTS) and Ischemic Core Volume to Determine the Malignant Profile in Acute Stroke. J Am Heart Assoc. 2019 Nov 19;8(22):e012558. doi: 10.1161/JAHA.119.012558. Epub 2019 Nov 8. PubMed 31698986 ↗
  • Fujita K, Tanaka K, Yamagami H, Ide T, Ishiyama H, Sonoda K, Satow T, Takahashi JC, Ihara M, Koga M, Yokota T, Toyoda K. Detrimental Effect of Chronic Hypertension on Leptomeningeal Collateral Flow in Acute Ischemic Stroke. Stroke. 2019 Jul;50(7):1751-1757. doi: 10.1161/STROKEAHA.119.025142. Epub 2019 May 16. Erratum In: Stroke. 2019 Sep;50(9):e280-e281. doi: 10.1161/STR.0000000000000204. PubMed 31233392 ↗
  • Takasugi J, Yamagami H, Noguchi T, Morita Y, Tanaka T, Okuno Y, Yasuda S, Toyoda K, Gon Y, Todo K, Sakaguchi M, Nagatsuka K. Detection of Left Ventricular Thrombus by Cardiac Magnetic Resonance in Embolic Stroke of Undetermined Source. Stroke. 2017 Sep;48(9):2434-2440. doi: 10.1161/STROKEAHA.117.018263. Epub 2017 Aug 17. PubMed 28818863 ↗
  • Hashimoto T, Hayakawa M, Funatsu N, Yamagami H, Satow T, Takahashi JC, Nagatsuka K, Ishibashi-Ueda H, Kira JI, Toyoda K. Histopathologic Analysis of Retrieved Thrombi Associated With Successful Reperfusion After Acute Stroke Thrombectomy. Stroke. 2016 Dec;47(12):3035-3037. doi: 10.1161/STROKEAHA.116.015228. Epub 2016 Oct 25. PubMed 27780903 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2016 (actual). Primary completion is estimated for Mar 2027, 125 months after the start.

Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 125 months is above that.

Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2014
First posted
Sep 29, 2014
StartActual
Oct 2016
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2028
Last update
Nov 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02251665
Lead sponsor
National Cerebral and Cardiovascular Center, Japan
Responsible party
Kazunori Toyoda (Director and Chair, Dept. of Stroke and Cerebrovascular Diseases, National Cerebral and Cardiovascular Center, Japan) — Principal investigator
First posted
Sep 29, 2014
Start date
Oct 2016
Primary completion
Mar 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 9, 2023

Study contacts

Kazunori Toyoda, MD, PhD
principal investigator · Vice Director of the Hospital, National Cerebral and Cardiovascular Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion